Literature DB >> 6138081

Pharmacokinetic and clinical considerations in the choice of a hypnotic.

R Amrein, M Eckert, H Haefeli, B Leishman.   

Abstract

Not only has insomnia become much more frequent in the last hundred years but its causes have also changed considerably. In the treatment of insomnia, benzodiazepines--because of their additional anxiolytic effect--offer substantial advantages over other sleep-inducing agents. The residual fraction--the quotient of plasma concentration at 12 h after drug intake to maximum plasma concentration--makes it possible to differentiate between the benzodiazepines according to their suitability as anxiolytics or hypnotics. Midazolam has the lowest residual fraction of all known benzodiazepines and thus, administered in the appropriate dosage, also has the shortest duration of activity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6138081      PMCID: PMC1428092          DOI: 10.1111/j.1365-2125.1983.tb02265.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  Pharmacokinetics of flunitrazepam following single- and multiple-dose oral administration to healthy human subjects.

Authors:  H G Boxenbaum; H N Posmanter; T Macasieb; K A Geitner; R E Weinfeld; J D Moore; A Darragh; D A O'Kelly; L Weissman; S A Kaplan
Journal:  J Pharmacokinet Biopharm       Date:  1978-08

2.  Bioavailability from various galenic formulations of flunitrazepam.

Authors:  J P Cano; M Soliva; D Hartmann; W H Ziegler; R Amrein
Journal:  Arzneimittelforschung       Date:  1977

3.  Pharmacokinetics and bioavailability of midazolam in man.

Authors:  P Heizmann; M Eckert; W H Ziegler
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

4.  [Pharmacokinetics of soporific drugs].

Authors:  R Amrein; M Eckert
Journal:  ZFA (Stuttgart)       Date:  1980-06-10

5.  Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease.

Authors:  U Klotz; K H Antonin; H Brügel; P R Bieck
Journal:  Clin Pharmacol Ther       Date:  1977-04       Impact factor: 6.875

6.  Absorption and excretion of 7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one (oxazepam) in humans. Determination of the drug by gas-liquid chromatography with electron capture detection.

Authors:  J A Knowles; H W Ruelius
Journal:  Arzneimittelforschung       Date:  1972-04
  6 in total
  5 in total

1.  Pharmacokinetics and pharmacodynamics following single and repeated nightly administrations of loprazolam, a new benzodiazepine hypnotic.

Authors:  G T McInnes; E A Bunting; R M Ings; J Robinson; S I Ankier
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

2.  Midazolam: sleep and performance studies in middle age.

Authors:  A N Nicholson; B M Stone
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

3.  Consensus on drug treatment, definition and diagnosis for insomnia.

Authors:  E Estivill; A Bové; D García-Borreguero; J Gibert; J Paniagua; G Pin; F J Puertas; R Cilveti
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

Review 4.  Midazolam. A review of its pharmacological properties and therapeutic use.

Authors:  J W Dundee; N J Halliday; K W Harper; R N Brogden
Journal:  Drugs       Date:  1984-12       Impact factor: 9.546

5.  Risk factors for excessive benzodiazepine use in a working age population: a nationwide 5-year survey in Norway.

Authors:  Ingunn Fride Tvete; Trine Bjørner; Tor Skomedal
Journal:  Scand J Prim Health Care       Date:  2015       Impact factor: 2.581

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.